Therapeutics News and Research

RSS

Ohr Pharmaceutical declares 1-for-3 reverse split of its outstanding common stock

Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.

3 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Study shows utility of cfDNA blood tests for breast cancer patients

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.

1 Jun 2013

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013.

1 Jun 2013

Nanoparticle-based immunotherapy for cancer

The German Research Foundation has established a new Collaborative Research Center on "Nanodimensional polymer therapeutics for tumor therapy" (CRC 1066) at Johannes Gutenberg University Mainz and the Max Planck Institute for Polymer Research (MPI-P).

1 Jun 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Vanda Pharmaceuticals announces submission of tasimelteon NDA to FDA

Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.

31 May 2013

Discovery opens doors to new therapies for sepsis

Despite numerous advances in treating infections and disease, effective treatments for sepsis remain elusive. A new discovery published in the June 2013 issue of The FASEB Journal not only could help health care providers predict who is more and less likely to develop sepsis, but it also opens the doors to new therapies that actually address the root cause of the problem, rather than just managing the symptoms.

31 May 2013

Safer, more effective treatment option for ovarian cancer

A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer.

31 May 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Doctors at the Texas Heart Institute at St. Luke's Episcopal Hospital announced that they have performed an investigational procedure on six patients in a new FDA-approved clinical trial to evaluate therapy that uses regenerative cells derived from a patient's own adipose (body fat) tissue to treat a severe form of heart failure.

30 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

29 May 2013

Protein presenilin plays critical role in controlling neuronal traffic on microtubule highways

Imagine if you could open up your brain and look inside. What you would see is a network of nerve cells called neurons, each with its own internal highway system for transporting essential materials between different parts of the cell.

29 May 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.

28 May 2013

Researchers develop multicolor fluorescence labeling method to identify tumor specific miRNAs

In recent years, microRNAs and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers.

27 May 2013

Researchers discover how drug prevents cancer progression

In collaboration with Daniel Zenklusen, also a University of Montreal biochemistry professor and lead author and doctoral candidate Vincent Messier, discovered that when cells are starved for nutrients TOR sends a signal to shut down production of a chemical message in the form of RNA to synthesize B cyclin ", Dr. Michnick explained.

24 May 2013

Echo Therapeutics unveils Symphony CGM System

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the successful unveiling and demonstration of its Symphony CGM System during a live webcast following yesterday's annual stockholders meeting.

24 May 2013

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

23 May 2013

Therapeutics News and Research

Ohr Pharmaceutical declares 1-for-3 reverse split of its outstanding common stock

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Study shows utility of cfDNA blood tests for breast cancer patients

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Nanoparticle-based immunotherapy for cancer

GLYX-13 drug induces antidepressant results without street drug side effects

Vanda Pharmaceuticals announces submission of tasimelteon NDA to FDA

Discovery opens doors to new therapies for sepsis

Safer, more effective treatment option for ovarian cancer

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Protein presenilin plays critical role in controlling neuronal traffic on microtubule highways

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Researchers develop multicolor fluorescence labeling method to identify tumor specific miRNAs

Researchers discover how drug prevents cancer progression

Echo Therapeutics unveils Symphony CGM System

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News